The advantages of using triple-marker screening for chromosomal abnormalities

This publication has 12 references indexed in Scilit:

• Second‐trimester maternal serum screening using alpha‐fetoprotein, human chorionic gonadotrophin, and unconjugated oestriol: Experience of a regional programme
  Prenatal Diagnosis, 1994
• A prospective trial of prenatal screening for Down syndrome by means of maternal serum α-fetoprotein, human chorionic gonadotropin, and unconjugated estriol
  American Journal of Obstetrics and Gynecology, 1993
• Prospective intervention trial of a screening protocol to identify fetal trisomy 18 using maternal serum alpha-fetoprotein, unconjugated oestriol, and human chorionic gonadotropin
  Prenatal Diagnosis, 1992
• Prenatal Screening for Down's Syndrome with Use of Maternal Serum Markers
  New England Journal of Medicine, 1992
• Antenatal maternal serum screening for Down's syndrome: results of a demonstration project.
  BMJ, 1992
• Prospective evaluation of maternal serum human chorionic gonadotropin levels in 3428 pregnancies
  American Journal of Obstetrics and Gynecology, 1991
• Maternal serum screening for Down's syndrome in early pregnancy.
  BMJ, 1988
• Low second trimester maternal serum unconjugated oestriol in pregnancies with Down's syndrome
  BJOG: An International Journal of Obstetrics and Gynaecology, 1988
• Abnormal maternal serum chorionic gonadotropin levels in pregnancies with fetal chromosome abnormalities
  Prenatal Diagnosis, 1987
• An association between low maternal serum α-fetoprotein and fetal chromosomal abnormalities
  American Journal of Obstetrics and Gynecology, 1984